Drugs / GKL-006
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07713290 | Apr 2025 → Nov 2026 expected | hepatocellular carcinoma | Beijing Gene Key Life Technology Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07209813 | Oct 2025 → Oct 2026 expected | hepatocellular carcinoma | Beijing Gene Key Life Technology Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GKL-006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07713290 ↗ |
| Modality | Cell therapy | “An iNKT cell therapy” NCT07713290 ↗ |
| Route | Intravenous | “IV single infusion” NCT07209813 ↗ |